anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: Obtaining blood cultures (HC) is performed in 15% of the patients treated with suspicion of infection in the Hospital Emergency Services (ED) with a variable diagnostic yield (2-20%). The 30-day mortality of patients with bacteremia is two or three times higher than the rest with the same process. Procalcitonin (PCT) is a biomarker that has been used as a tool to help predict bacteremia in HEDs. The main objective of this systematic review is to investigate the diagnostic accuracy of PCT in predicting true bacteraemia in adult patients treated with clinical suspicion of infection in the ED, as well as to identify a specific PCT value as the most relevant from the clinical decision diagnostic point of view that can be recommended for decision making.
METHODS: A systematic review was performed following the PRISMA guidelines in the PubMed, Web of Science, EMBASE, Lilacs, Cochrane, Epistemonikos, Tripdatabase and ClinicalTrials.gov databases from January 2010 to May 31, 2023 without language restrictions and using a combination of MESH terms: "Bacteremia/ Bacteraemia/ Blood Stream Infection", "Procalcitonin", "Emergencies/ Emergency/ Emergency Department" and "Adults". Observational cohort studies and partially an systematic review were included. No meta-analysis techniques were performed, but the results were compared narratively.
RESULTS: A total of 1,372 articles were identified, of which 20 that met the inclusion criteria were finally analyzed. The included studies represent a total of 18,120 processed HC with 2,877 bacteraemias (15.88%). Ten studies were rated as high, 9 moderate and 1 low quality. The AUC-COR of all the studies ranges from 0.68 (95% CI: 0.59-0.77) to 0.98 (95% CI: 0.97-0.99). The PCT value >0.5 ng/ml is the most widely used and proposed in up to ten of the works included in this systematic review, whose estimated mean yield is an AUC-COR of 0.833. If only the results of the 6 high-quality studies using a cut-off point (PC) >0.5 ng/mL PCT are taken into account, the estimated mean AUC-COR result is 0.89 with Se of 77.6% and It is 78%.
CONCLUSIONS: PCT has a considerable diagnostic accuracy of bacteraemia in patients treated in EDs for different infectious processes. The CP>0.5 ng/ml has been positioned as the most suitable for predicting the existence of bacteraemia and can be used to reasonably rule it out.
This invention relates to biologically-active polymers that are useful for analyte detection and isolation and delivery of substances. The biologically-active polymers are capable of specifically and reversibly binding to analytes, including molecules and cells. The biologically-active polymers are also capable of releasing substances upon electrical stimulation. The present invention provides compositions comprising biologically-active polymers membranes and methods for making these biologically-active polymers membranes that may be specifically designed to selectively bind cells and specific cell types, to affect cell growth characteristics, and to modulate cellular differentiation. These biologically-active polymers membranes may be controlled electrically to induce controlled cellular differentiation and modulate the cell growth cycle. These biologically-active polymers have many applications in biological and chemical fields.
OBJECTIVES: Visual analogue scale (VAS) and numeric rating scale (NRS) are two commonly used instruments for measuring pain intensity. Both instruments are validated for use in both clinical and research settings, and share a range of similar aspects. Some studies have shown that the two instruments may be used interchangeably, but the results are conflicting. In this study we assessed whether the VAS and the NRS instruments may be used interchangeably when measuring pain intensity in older adults.
METHODS: Data were collected in a cross-sectional study, as part of the follow-up in a larger longitudinal study conducted at the Akershus University Hospital, Norway 2021 to 2022 and included 39 older adults aged ≥65. Participants were regarded as a normal older adult population as they were not recruited on basis of a specific condition or reports of pain. The participants were asked to rate their pain intensity on an average day using VAS and NRS. Bland-Altman analysis was performed to assess agreement between the two instruments.
RESULTS: Thirty-seven participants with mean (SD) age of 77 (5.9) were included in the analysis. Mean (SD) pain assessed by VAS and NRS was 2.8 (1.8) and NRS 4.7 (2.2), respectively. A mean difference (SD) of 2.0 (1.9) between the scores of the two instruments was statistically significantly different from zero (p < 0.001) confirming bias. The 95% limits of agreement were estimated to be -1.7 to 5.7. A post-hoc analysis, removing an outlier, resulted in similar conclusions.
CONCLUSION: There was poor agreement between the VAS and NRS scale for measuring pain intensity in older adults. This suggests that the two instruments should not be used interchangeably when assessing pain intensity in this population.
ETHICAL APPROVAL: Regional Committees for Medical and Health Research Ethics [2016/2289].
TRIAL REGISTRATION: NCT03162081, 22 May 2017.
The invention discloses medicine for curing scapulohumeral periarthritis and a preparing method, and belongs to the field of traditional Chinese medicine. The medicine is prepared from the following raw materials of fructus eucalyptus globules labill, radix angelicae dahurica, rhizoma seu radix notopterygii, purslane speedwell herb, ficus pumila linn, flos woodfordia fruticosa, banyan leaves, stephania sinica, radix wikstroemia indica, herba piper boehmeriaefolium, henry ormosia wood, herba ipomoea pes-caprae, radix stachys sieboldii, herba phlomis umbrosa, radix schoepfia jasminodora and radix reineckia carnea. The medicinal materials of the medicine are in compatibility, can meet theories of traditional Chinese medicine and modern medicine and pharmacology, and has the efficacies of dispelling wind and relaxing muscles and tendons, relieving swelling and dispersing blood stasis, and promoting blood circulation and stopping pain. Thus, the medicine has an obvious curing effect on scapulohumeral periarthritis. Furthermore, the medicine is short in curing course, quick in effect, convenient to take, low in cost, safe and free of side effects, can achieve the purpose of treating both symptoms and root causes and is worth of widely popularizing and applying clinically. In addition, the scapulohumeral periarthritis is not prone to relapsing after being cured.
The invention discloses a traditional Chinese medicine decoction for defervescence of children, and a preparation method thereof. The method comprises the following steps: cleaning dichondra repens and rice, of which the weight ratio is 1:1 as raw materials; carrying out pretreatment; preparing rice water and decoction, so as to obtain the traditional Chinese medicine decoction. The traditional Chinese medicine decoction for defervescence of children is prepared by utilizing the dichondra repens as a main raw material; the traditional Chinese medicine decoction is convenient to orally take; the body temperature can get right after the traditional Chinese medicine decoction is taken 1-3 doses in general. The defervescence effect is significant by repeated clinical verification of child sufferers. In addition, the dichondra repens and rice used by the traditional Chinese medicine decoction are the raw materials which are low in price, convenient and available, and the preparation process is simple in operation, and easy to learn and understand. More important, the traditional Chinese medicine decoction for defervescence disclosed by the invention is free of obvious toxic and side effects, and is an effective prescription for defervescence, which is especially applicable to taking by child sufferers with mild-to-moderate fevers.
All participants will receive Atezolizumab, Bevacizumab,Sorafenib and cyclophosphamide until maximum tolerated dose is reached.Tolerability will be defined after completion of Course 1. Part 2 will begin once the recommended phase 2 dose (RP2D) is determined.
BACKGROUND: Many gastric cancer patients in Western countries are diagnosed as metastatic with a median overall survival of less than twelve months using standard chemotherapy. Innovative treatments, like targeted therapy or immunotherapy, have recently proved to ameliorate prognosis, but a general agreement on managing oligometastatic disease has yet to be achieved. An international multi-disciplinary workshop was held in Bertinoro, Italy, in November 2022 to verify whether achieving a consensus on at least some topics was possible.
METHODS: A two-round Delphi process was carried out, where participants were asked to answer 32 multiple-choice questions about CT, laparoscopic staging and biomarkers, systemic treatment for different localization, role and indication of palliative care. Consensus was established with at least a 67% agreement.
RESULTS: The assembly agreed to define oligometastases as a "dynamic" disease which either regresses or remains stable in response to systemic treatment. In addition, the definition of oligometastases was restricted to the following sites: para-aortic nodal stations, liver, lung, and peritoneum, excluding bones. In detail, the following conditions should be considered as oligometastases: involvement of para-aortic stations, in particular 16a2 or 16b1; up to three technically resectable liver metastases; three unilateral or two bilateral lung metastases; peritoneal carcinomatosis with PCI ≤ 6. No consensus was achieved on how to classify positive cytology, which was considered as oligometastatic by 55% of participants only if converted to negative after chemotherapy.
CONCLUSION: As assessed at the time of diagnosis, surgical treatment of oligometastases should aim at R0 curativity on the entire disease volume, including both the primary tumor and its metastases. Conversion surgery was defined as surgery on the residual volume of disease, which was initially not resectable for technical and/or oncological reasons but nevertheless responded to first-line treatment.
Participants will have a 50% chance of receiving the placebo for this study. They will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 8-10 weeks.
Conventional exercises (with the addition of warm-up and cool-down periods) will be applied to all multiple sclerosis patients participating in the study; In addition, aerobic exercise training will be given. In addition to these exercises, plantar sensory training will be given to the sensory training group. Exercises and plantar sensory training will be given to the participants at intervals of three weeks, with progressively progressive sessions, 2 days a week for 12 weeks. Patients will be evaluated twice, before treatment and at the end of treatment 12 weeks later. Within the scope of the evaluation, balance, functional capacity, gait, proprioception and plantar sensory parameters will be measured in patients.
Disclosed are yeast cells expressing a polypeptide comprising a signal sequence and a human ApoE protein. In some embodiments the polypeptide comprises ApoE2. In some embodiments the polypeptide comprises ApoE3. In some embodiments the polypeptide comprises ApoE4. Also disclosed are methods of screening yeast cells to identify compounds that prevent or suppress Apo-induced toxicity. Compounds identified by such screens can be used to treat or prevent neurodegenerative disorders such as Alzheimer's disease. Also disclosed are methods of screening yeast cells to identify genetic suppressors or enhancers of ApoE-induced toxicity. Also disclosed are genetic suppressors or enhancers of ApoE-induced toxicity identified using the methods, and human homologs thereof. Also disclosed are methods of identifying compounds that modulate expression or activity of genetic modifiers of ApoE-induced toxicity.
Obesity impairs tissue insulin sensitivity and signaling, promoting type-2 diabetes. Although improving insulin signaling is key to reversing diabetes, the multi-organ mechanisms regulating this process are poorly defined. Here, we screen the secretome and receptome in Drosophila to identify the hormonal crosstalk affecting diet-induced insulin resistance and obesity. We discover a complex interplay between muscle, neuronal, and adipose tissues, mediated by Bone Morphogenetic Protein (BMP) signaling and the hormone Bursicon, that enhances insulin signaling and sugar tolerance. Muscle-derived BMP signaling, induced by sugar, governs neuronal Bursicon signaling. Bursicon, through its receptor Rickets, a Leucine-rich-repeat-containing G-protein coupled receptor (LGR), improves insulin secretion and insulin sensitivity in adipose tissue, mitigating hyperglycemia. In mouse adipocytes, loss of the Rickets ortholog LGR4 blunts insulin responses, showing an essential role of LGR4 in adipocyte insulin sensitivity. Our findings reveal a muscle-neuronal-fat-tissue axis driving metabolic adaptation to high-sugar conditions, identifying LGR4 as a critical mediator in this regulatory network.
Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3.beta.]-androsta-4,16-dien-3-ol. In some embodiments of the methods, both [3.beta.}-androsta- 4,16-dien-3-ol and [3.alpha.]-androsta-4,16-dien-3-ol are administered to a patient, and are included in a pharmaceutical composition for the treatment of social phobia.
A drive mechanism for delivery of infusion medium in an implantable medical device includes an inlet for receiving the infusion medium and a piston channel for communication of infusion medium received by the inlet. The piston channel has a distal end and a proximal end. The proximal end is closer to the inlet than the distal end. The drive mechanism further includes a coil surrounding the piston channel and a piston located within the piston channel and moveable axially within the piston channel to drive infusion medium out of the distal end of the piston channel. The mechanism also includes an armature operably coupled to the piston and disposed adjacent the coil. The armature has first and second opposing major surfaces and a plurality of vents extending through the armature from the first major surface to the second major surface. The plurality of vents cumulatively occupy between about 20% and about 40% of the total surface area of the first major surface. Electromagnetic interaction between the armature and the coil cause the piston move in the channel.
Myorisan® must not be used by female patients who are or may become pregnant. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking Myorisan® in any amount, even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining whether an exposed fetus has been affected. 

  
Birth defects which have been documented following Myorisan® exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. Cases of IQ scores less than 85 with or without other abnormalities have been reported. There is an increased risk of spontaneous abortion, and premature births have been reported. 

Documented external abnormalities include: skull abnormality; ear abnormalities (including anotia, micropinna, small or absent external auditory canals); eye abnormalities (including microphthalmia); facial dysmorphia; cleft palate. Documented internal abnormalities include: CNS abnormalities (including cerebral abnormalities, cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficit); cardiovascular abnormalities; thymus gland abnormality; parathyroid hormone deficiency. In some cases death has occurred with certain of the abnormalities previously noted. 

If pregnancy does occur during treatment of a female patient who is taking Myorisan®, Myorisan® must be discontinued immediately and she should be referred to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling.

Special Prescribing Requirements

Because of Myorisan’s ®teratogenicity and to minimize fetal exposure, Myorisan® is approved for marketing only under a special restricted distribution program approved by the Food and Drug Administration. This REMS is called iPLEDGE®. Myorisan® must only be prescribed by prscribers who are enrolled and activated with the iPLEDGE REMS. Myorisan® must only be

dispensed by a pharmacy enrolled and activated with iPLEDGE, and must only be dispensed to patients who are enrolled and meet all the requirements of iPLEDGE. (see PRECAUTIONS).
Observational arm. Adults (18+ years) with type 1 OI. Changes in hearing, quality of life, and bone density will be monitored.
Patients will receive one cycle of AZA through the vein or as a shot under the skin daily for 5 days. This will start at the same time or within 3 days of starting standard treatment for gut GVHD with steroids.
The invention relates to cosmetic compositions containing agglomerates with particular particle sizes. The compositions are characterized in that they contain spherical non-porous SiO2 particles with a particle size of 0.05-1.5 .mu.m, and other inorganic particle-shaped materials with spherical structure. The spherical SiO2 and the other inorganic materials form defined agglomerates with a particle size of 0.06 .mu.m to 5 .mu.m. The proportion of agglomerates in the cosmetic composition is between 0.1 and 30 %wt. The aggregatecontaining dispersions are produced by introducing the spherical SiO2 step by step and in special conditions. Formulations produced with these aggregates are characterized by particularly stable and high sunscreen factors.
Hyponatremic patients (serum sodium \<135mmol/L): tolvaptan 3.75 mg tablet; The serum sodium concentration was controlled at 6:00 pm. Those patients, whose serum sodium concentration further dropped below 132 mmol/L, were treated with a second tablet of tolvaptan and the serum sodium was measured the next day at 8:00 am. Those patients, whose serum sodium was increased by not more than 5 mmol/L underwent the next blood check on the next day at 8:00 am. Those patients, whose serum sodium increased by more than 5 mmol/L were treated by 1L tea/water or a 500 mL 5% glucose infusion.
Stainless steel crowns have been the most common treatment for large cavities in baby teeth until recently. These crowns are silver in color, and aesthetically are not a good option for restoring front teeth. Several tooth colored options have been developed to meet the growing demand for more aesthetics on front teeth. With the variety of new options for restoring anterior primary teeth, the investigators would like to evaluate the long-term success of three tooth-colored restoration options: NuSmile Signature crowns, NuSmile ZR crowns, and composite crowns. The investigators are interested in looking at the outcomes of these three restoration types, in terms of durability, aesthetics and cost effectiveness for the treatment of front baby teeth. The purpose of this pilot study is to evaluate the clinical performance of two types of NuSmile crowns compared to composite crowns in treating large multi-surfaced cavities on front baby teeth.
Allergy is a hypersensitivity reaction to a triggering agent. Tests used in allergy are divided into two: in vivo and in vitro. Among the in vivo tests routinely used, epidermal, intradermal and patch tests are used, and the most commonly used is the skin prick test. In order to prevent the negative effects of pain, it is important to be informed about the appropriate approach to children, newborns and babies, and effective pain management, according to their cognitive development levels. Pain management in children should be done appropriately with accurate assessment tools. This will increase the quality of life, reduce hospitalizations, shorten the length of hospital stay and reduce costs. Pain experiences experienced during childhood will cause later pain experiences to be perceived as more severe and cause anxiety and fear. Anxiety is a psychological, physiological and behavioral state that develops in response to a perceived or existing threat. Anxiety, which can also be expressed as worry or anxiety, is a emotional state that can occur in various ways, such as restlessness, tension, easy fatigue, lack of concentration, muscle tension, and sleep disturbance, in which autonomic and somatic symptoms occur in the body, without any reason.

Virtual reality provides multi-sensory information as children focus on the simulated world. Virtual reality, one of the cognitive methods; It can create an environment where three-dimensional pictures or animations created on the computer can interact in people's minds. It is also defined as a distraction method created by software, which creates the feeling that users are in the environment even though they are not in the real environment, and can interact with people in the environment.

When all these studies were examined, no three-group study was found comparing a distracting method with a physical method for the 7-10 age group. Additionally, there is a study that used virtual reality in the prick test, but there is no method that has been proven to be superior to virtual reality. In this study, it will be investigated whether virtual reality and buzzy applications have a reducing effect on pain, fear and anxiety compared to the control group. Virtual reality and buzzy techniques will also be compared with each other. Since no such study has been found in the literature, it is thought to contribute to the field.
Preparations of the hormone of the suprarenal cortex are obtained free from the toxic action of 1-(3 : 4 dihydroxy-phenyl)2-methyl-amino-ethanol-1, by treating the cortex, or the whole suprarenal capsule, or any preparations obtained from these, with formaldehyde or a compound capable of splitting off formaldehyde, such as formaldehyde-bisulphite orsulphoxylate.  It is stated that the formaldehyde forms condensation products, of unknown constitution, which are physiologically inactive.  Any excess of the aldehyde may be eliminated by adding ammonia.  The treatment with formaldehyde may take place in feebly alkaline, neutral, or feebly acid solution or suspension, or powdered suprarenal cortex may be treated with gaseous formaldehyde before the hormone is extracted. Examples are given.  Known processes for eliminating dehydroxyphenyl - methylamino-ethanol from preparations of the hormone of suprarenal cortex by treatment with potassium permanganate or hydrogen peroxide, are referred to.